Amoxicillin-Clavulanate Breakpoints Against Haemophilus influenzae: Rationale for Revision by the Clinical and Laboratory Standards Institute is a research paper published in Clinical Infectious Diseases (2024). On theSindex it has a DataRank of 0.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health
Grant: K23AI159396
Abbott
Qpex Biopharma
American Society for Clinical Laboratory Science
Ferring Pharmaceuticals
Merck and Shionogi Inc
Shionogi Inc
Beckman Coulter
Venatorx Pharmaceuticals
Merck
Abbvie Inc.
Cepheid, Inc
European Committee on Antimicrobial Susceptibility Testing
National Institute of Allergy and Infectious Diseases
Astellas Pharma
Melinta Therapeutics
FWCI
0.00
Citation Percentile
0.1%
Fields of Study
Keywords
Sustainable Development Goals